Kymera Therapeutics, Inc.
NASDAQ:KYMR
40.11 (USD) • At close December 27, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Kymera Therapeutics, Inc. |
Symbool | KYMR |
Munteenheid | USD |
Prijs | 40.11 |
Beurswaarde | 2,597,736,183 |
Dividendpercentage | 0% |
52-weken bereik | 22.35 - 53.27 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Nello Mainolfi M.D., Ph.D. |
Website | https://www.kymeratx.com |
An error occurred while fetching data.
Over Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)